 SAN JOSE, Calif., Oct. 1, 2021 PRNewswire -- Anixa Biosciences, Inc. NASDAQ: ANIX Anixa, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office USPTO has issued a Notice of Allowance broadening protection of Anixas novel Chimeric Antigen Receptor-T cell CAR-T cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, Follicle Stimulating Hormone Receptor-Mediated CAR-T technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center. 